Cerus (NASDAQ:CERS) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Thursday, January 4th.

Other analysts have also recently issued research reports about the company. Zacks Investment Research cut Cerus from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. BTIG Research restated a “neutral” rating on shares of Cerus in a research note on Friday, December 8th. Cowen set a $6.00 target price on Cerus and gave the stock a “buy” rating in a research note on Thursday, October 5th. BidaskClub lowered Cerus from a “sell” rating to a “strong sell” rating in a research note on Friday, December 29th. Finally, Robert W. Baird reiterated a “buy” rating and set a $5.00 price objective on shares of Cerus in a research note on Friday, December 1st. Two analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $5.83.

Shares of Cerus (NASDAQ CERS) opened at $4.88 on Thursday. Cerus has a fifty-two week low of $1.93 and a fifty-two week high of $5.43. The firm has a market capitalization of $556.74, a P/E ratio of -8.27 and a beta of 1.93. The company has a quick ratio of 3.11, a current ratio of 3.71 and a debt-to-equity ratio of 0.80.

Cerus (NASDAQ:CERS) last announced its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.03. The company had revenue of $10.80 million for the quarter, compared to analysts’ expectations of $11.95 million. Cerus had a negative return on equity of 142.18% and a negative net margin of 159.35%. Cerus’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.14) earnings per share. research analysts anticipate that Cerus will post -0.58 EPS for the current year.

Several institutional investors have recently modified their holdings of CERS. Premier Asset Management LLC purchased a new stake in shares of Cerus during the 3rd quarter valued at approximately $348,000. Vanguard Group Inc. raised its position in Cerus by 3.9% in the second quarter. Vanguard Group Inc. now owns 4,892,503 shares of the biotechnology company’s stock valued at $12,281,000 after purchasing an additional 184,076 shares during the period. Elk Creek Partners LLC raised its position in Cerus by 32.3% in the second quarter. Elk Creek Partners LLC now owns 5,739,285 shares of the biotechnology company’s stock valued at $14,406,000 after purchasing an additional 1,402,106 shares during the period. First Midwest Bank Trust Division raised its position in Cerus by 50.3% in the third quarter. First Midwest Bank Trust Division now owns 1,078,277 shares of the biotechnology company’s stock valued at $2,944,000 after purchasing an additional 360,785 shares during the period. Finally, Northern Trust Corp increased its position in shares of Cerus by 3.2% during the second quarter. Northern Trust Corp now owns 1,269,773 shares of the biotechnology company’s stock worth $3,186,000 after acquiring an additional 39,684 shares during the period. Institutional investors and hedge funds own 55.77% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was originally published by Marea Informative and is owned by of Marea Informative. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.mareainformativa.com/2018/01/30/cerus-cers-upgraded-at-valuengine-updated-updated-updated.html.

About Cerus

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.